Private Equity's Growing Role in Medical Aesthetics: What It Means for Patients

Private equity has discovered medical aesthetics. Over the past five years, PE firms have invested billions of dollars acquiring dermatology practices, medical spas, laser clinics, and aesthetic surgery groups, aggregating them into larger platform companies. The transformation is ongoing and accelerating, with implications that extend from industry structure to patient care standards.

The Scale of PE Investment

Estimates suggest PE firms have completed over 1,000 acquisitions in U.S. dermatology and aesthetic medicine since 2015, with total capital deployed in the multi-billions. Dermatology is attractive because it combines predictable revenue streams, high patient volumes, relatively predictable margins, fragmented ownership (many small practices available for acquisition), and favorable demographic trends. Aesthetic clinics with high tattoo removal volumes are especially attractive due to multi-session treatment protocols creating recurring revenue visibility.

PE Acquisition Business Model

The typical PE roll-up playbook involves acquiring a high-quality platform practice, acquiring additional practices in complementary markets, implementing standardized operations and shared services, growing EBITDA through revenue growth and margin improvement, then selling the enlarged platform to a larger buyer 4–7 years after initial investment. The standardization phase often involves implementing uniform pricing, standardizing technology, and centralizing decision-making away from individual practitioners.

Patient Implications

PE ownership has mixed implications for patients. Capital can fund better technology, expanded hours, additional locations, and improved patient communication systems. However, profit orientation creates incentives that can conflict with patient-optimal care: incentives to increase treatment volumes, reduce consultation time, and reduce physician oversight where regulation permits. Patients should evaluate specific practitioners, technology, protocols, and complication management rather than ownership structure alone.

Regulatory Response

Rapid PE growth in medical practices has attracted regulatory scrutiny. Several states have strengthened enforcement of corporate practice of medicine doctrines. The FTC has reviewed certain large acquisitions. Medical professional associations have raised concerns about profit-oriented ownership influencing clinical decision-making.